


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A pharmaceutical agent comprising an antiplatelet agent a compound selected from the group consisting of aspirin, dipyridamole, cilostazol, ticlopidine and clopidogrel in combination with a 5-amidino-2-hydroxybenzene-sulfonamide derivative represented by the general formula:



wherein R represents a hydrogen atom or a lower alkyl group; and Z represents a hydrogen atom or a hydroxy group, or a pharmaceutically acceptable salt thereof.


Claims 2-3 (canceled).

4. (original): A pharmaceutical agent as claimed in claim 1, wherein the 5-amidino-2-hydroxybenzenesulfonamide derivative is a compound selected from the group consisting of n-butyl [4-[2-[2-hydroxy-5-(N-hydroxycarbamimidoyl)benzenesulfonyl-amino]ethyl]-2'-

methanesulfonylbiphenyl-3-yloxy]acetate, [4-[2-[2-hydroxy-5-(N-hydroxycarbamimidoyl)benzenesulfonyl-amino]ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetic acid, n-butyl [4-[2-(5-amidino-2-hydroxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetate and [4-[2-(5-amidino-2-hydroxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetic acid.

Claims 5-9 (canceled).

10. (withdrawn/currently amended): A method for the prevention or treatment of thromboembolism, which comprises administering an effective amount of an antiplatelet agent a compound selected from the group consisting of aspirin, dipyridamole, cilostazol, ticlopidine and clopidogrel in combination with an effective amount of a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula:




wherein R represents a hydrogen atom or a lower alkyl group; and Z represents a hydrogen atom or a hydroxy group, or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

Claim 11 (canceled).

12. (withdrawn/previously presented): A method for the prevention or treatment of thromboembolism as claimed in claim 10, wherein the 5-amidino-2-hydroxybenzenesulfonamide derivative is a compound selected from the group consisting of n-butyl [4-[2-[2-hydroxy-5-(N-hydroxycarbamidoyl)benzene-sulfonylamino]ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]-acetate, [4-[2-[2-hydroxy-5-(N-hydroxycarbamidoyl)-benzenesulfonylamino]ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetic acid, n-butyl [4-[2-(5-amidino-2-hydroxy-benzenesulfonylamino)ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetate and [4-[2-(5-amidino-2-hydroxybenzene-sulfonylamino)ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]-acetic acid.

Claims 13-16 (canceled).

17. (withdrawn/currently amended): A method for inhibiting thrombus formation, which comprises administering an effective amount of ~~an antiplatelet~~ a compound selected from the group consisting of aspirin, dipyridamole, cilostazol, ticlopidine and clopidogrel agent in combination with an effective amount of a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula:



wherein R represents a hydrogen atom or a lower alkyl group; and Z represents a hydrogen atom or a hydroxy group, or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

Claims 18-25 (canceled).

26. (new/withdrawn): A method for the prevention or treatment of thromboembolism as claimed in claim 10, wherein the thromboembolism is arterial thromboembolism.

27. (new/withdrawn): A method for the prevention or treatment of thromboembolism as claimed in claim 12, wherein the thromboembolism is arterial thromboembolism.

28. (new/withdrawn): A method for the prevention or treatment as claimed in claim 26, wherein the arterial thromboembolism is unstable angina, cardiac infarction, cerebral thrombosis, atherothrombotic cerebral infarction, lacunar infarction, chronic arterial occlusive disease, cardiogenic embolism, peripheral arterial occlusive or embolism attributed to coronary intervention.

29. (new/withdrawn): A method for the prevention or treatment as claimed in claim 27, wherein the arterial thromboembolism is unstable angina, cardiac infarction, cerebral thrombosis, atherothrombotic cerebral infarction, lacunar infarction, chronic arterial occlusive disease, cardiogenic embolism, peripheral arterial occlusive or embolism attributed to coronary intervention.

30. (new/withdrawn): A method for the prevention or treatment as claimed in claim 10, wherein the thromboembolism is venous thromboembolism.

31. (new/withdrawn): A method for the prevention or treatment as claimed in claim 12, wherein the thromboembolism is venous thromboembolism.

32. (new/withdrawn): A method for the prevention or treatment as claimed in claim 30, wherein the venous thromboembolism is sinus thrombosis, traveler's thrombosis, pulmonary embolism or deep-vein thrombosis.

33. (new/withdrawn): A method for the prevention or treatment as claimed in claim 31, wherein the venous thromboembolism is sinus thrombosis, traveler's thrombosis, pulmonary embolism or deep-vein thrombosis.